1-3 of 3
Russell J. Garland
Close
Sort by
Journal Articles

Development of Clinical Scale Cytomegalovirus-Specific T Cells for Adoptive Immunotherapy Using pp65.

Paraskevi Diamanti, PhD, Russell J. Garland, PhD, Derwood H. Pamphilon, MD, Colin G. Steward, MD, PhD, Allison Blair, PhD
Journal: Blood
Blood (2005) 106 (11): 5250.
https://doi.org/10.1182/blood.V106.11.5250.5250
Published: 2005
Journal Articles

CMV Specific Immunotherapy: How Many Patients Will Benefit?.

Russell J. Garland, PhD, Paraskevi Diamanti, PhD, Samantha E. West, PhD, Ann Green, MSc, David Carrington, PhD, Sarah J. Groves, BSc, Kerri L. Winship, BSc, Stephen P. Robinson, MD, Anthony Oakhill, MD, Jacqueline M. Cornish, MD, Derwood H. Pamphilon, MD, David I. Marks, MD, Nicholas J. Goulden, MD, Allison G. Blair, PhD, Colin G. Steward, MD
Journal: Blood
Blood (2004) 104 (11): 2244.
https://doi.org/10.1182/blood.V104.11.2244.2244
Published: 2004
Journal Articles

Minimal Residual Disease Status Before Allogeneic Bone Marrow Transplantation Is an Important Determinant of Successful Outcome for Children and Adolescents With Acute Lymphoblastic Leukemia

Christopher J.C. Knechtli, Nicholas J. Goulden, Jeremy P. Hancock, Victoria L.G. Grandage, Emma L. Harris, Russell J. Garland, Claire G. Jones, Anthony W. Rowbottom, Linda P. Hunt, Ann F. Green, Emer Clarke, Alan W. Lankester, Jacqueline M. Cornish, Derwood H. Pamphilon, Colin G. Steward, Anthony Oakhill
Journal: Blood
Blood (1998) 92 (11): 4072–4079.
https://doi.org/10.1182/blood.V92.11.4072
Published: 1998